Literature DB >> 3029243

Protection from endotoxemia: a rat model of plasmapheresis and specific adsorption with polymyxin B.

J Cohen, M Aslam, C D Pusey, C J Ryan.   

Abstract

Polymyxin B (PB), a cyclic polypeptide antibiotic, has potent antiendotoxin properties but is associated with significant toxicity when given parenterally. As an alternative, PB was immobilized on a solid phase (Sepharose 4B; Pharmacia, Uppsala, Sweden), and a system of plasmapheresis was developed in the conscious rat, with specific on-line plasma adsorption of endotoxin by a PB-Sepharose column. PB-Sepharose columns removed 94% of a challenge dose of 5 micrograms of endotoxin in vitro. Rats were pretreated with lead acetate so that they were sensitized to endotoxin and then given 10 micrograms of endotoxin/kg intraarterially. After 15 min plasmapheresis was begun and continued for 90 min. Animals whose plasma was perfused over PB-Sepharose were protected from endotoxin-induced leukopenia (P less than .01), thrombocytopenia (P less than .001), and death (four of four survivors compared with none of four controls). Thus plasmapheresis with on-line removal of endotoxin is a safe and highly effective means of protecting animals from the effects of endotoxemia.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3029243     DOI: 10.1093/infdis/155.4.690

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  12 in total

1.  Successful therapy of meningococcal sepsis in acute disseminated lupus erythematosus with plasmapheresis, immunosuppression, and antibiotics.

Authors:  G J Dobos; S Meske; E Keller; W Riegel; P Vaith; H H Peter; P Schollmeyer
Journal:  Klin Wochenschr       Date:  1990-10-03

2.  Direct hemoperfusion with a polymyxin B-immobilized cartridge in intestinal warm ischemia reperfusion.

Authors:  Hiroaki Sato; Kiyohiro Oshima; Kazuhisa Arakawa; Katsumi Kobayashi; Hodaka Yamazaki; Yujin Suto; Izumi Takeyoshi
Journal:  World J Gastroenterol       Date:  2008-09-21       Impact factor: 5.742

Review 3.  Intensive care.

Authors:  S Sinclair; M Singer
Journal:  Postgrad Med J       Date:  1993-05       Impact factor: 2.401

Review 4.  Clinical relevance of antibiotic-induced endotoxin release.

Authors:  J M Prins; S J van Deventer; E J Kuijper; P Speelman
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

5.  Successful treatment of sepsis with polymyxin b-immobilized fiber hemoperfusion in a child after living donor liver transplantation.

Authors:  Yoshiyuki Morishita; Yoshiaki Kita; Kazuei Ohtake; Eiji Kusano; Shuji Hishikawa; Koichi Mizuta; Hideo Kawarasaki
Journal:  Dig Dis Sci       Date:  2005-04       Impact factor: 3.199

6.  Covalent polymyxin B conjugate with human immunoglobulin G as an antiendotoxin reagent.

Authors:  J J Drabick; A K Bhattacharjee; D L Hoover; G E Siber; V E Morales; L D Young; S L Brown; A S Cross
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

7.  Comparison of the binding of gram-negative bacterial endotoxin by polymyxin B sulphate, colistin sulphate and colistin sulphomethate sodium.

Authors:  M J Rogers; J Cohen
Journal:  Infection       Date:  1986 Mar-Apr       Impact factor: 3.553

8.  Hemoperfusion with polymyxin B-immobilized fiber column improves liver function after ischemia-reperfusion injury.

Authors:  Hiroaki Sato; Kiyohiro Oshima; Katsumi Kobayashi; Hodaka Yamazaki; Yujin Suto; Izumi Takeyoshi
Journal:  World J Gastroenterol       Date:  2009-09-28       Impact factor: 5.742

9.  Multiple organ failure--a role for plasma exchange?

Authors:  P McClelland; P S Williams; M Yaqoob; S M Mostafa; J M Bone
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

10.  Degradation of endogenous bacterial cell wall polymers by the muralytic enzyme mutanolysin prevents hepatobiliary injury in genetically susceptible rats with experimental intestinal bacterial overgrowth.

Authors:  S N Lichtman; E E Okoruwa; J Keku; J H Schwab; R B Sartor
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.